The objective of the research was to conduct a comparative analysis of 25(OH) vitamin D concentration in the serum of examined adults, patients with multiple sclerosis (MS), and the control group, depending on the clinical characteristics of the disease.
Materials and methods of the research. The study involved 68 patients with MS, including 39 women and 29 men with confirmed MS diagnosis. The average age of patients was 37.7 ± 9.7, an average severity according to EDSS scale constituted 4.7 ± 1.3 points. The control group consisted of 10 healthy individuals (an average age was 37.3 ± 8.7). The content of vitamin D in blood serum was determined by ELISA measured in nmol/l.
Results of the research. Our studies found a decrease of the vitamin D level in the serum of all examined 68 MS patients, as compared with practically healthy people (37.3 ± 1.7 mmol / L vs. 69.8 ± 3.3 nmol / L, respectively). Vitamin D concentration rates in the blood serum of patients with MS were found not to depend on the patients’ sex. A significant decrease of vitamin D was obsrved in patients with MS at the age of 30-40 compared with the group of patients at the age of 40-50 (33.2 ± 2.3 mmol / L vs. 42.0 ± 3.5 nmol / L, respectively). A significant decrease in vitamin D level was found among patients with Secondary-Progressive Multiple Sclerosis in comparison with the group of patients with Relapsing-Remitting MS. A statistically significant difference in vitamin D level was detected among patients with an average MS severity compared with a group of MS patients, where EDSS score was the highest.
Thus, the results of the research indicated that vitamin D deficiency in the serum of MS patients was probably one of the etiological factors of the disease. 25(OH)D concentration in the serum of MS patients depended on the clinical characteristics of the disease. Thus, patients with the most severe type of Secondary-Progressive Multiple Sclerosis and with the highest score according to EDSS had the lowest vitamin D level.
Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet Neurol. 2010; 9(6): 599-612.
Dobson R, Giovannoni G, Ramagopalan S. The month of birth effect in multiple sclerosis: systematic review, meta-analysis and effect of latitude. J Neurol Neurosurg Psychiatry. 2013; 84: 427-432.
Komisarenko YuI, Antonenko OV. The level of vitamin D and its connection with the contents of glycated hemoglobin in residents of Kyiv who suffer from diabetes mellitus. Endocrynolohiia. 2012; 2(17): 40-43.
Kvashina LV, Oniskova OV. Vitamin D sufficiency and the risk of development of cardiovascular system diseases. Sovremennaya pediatriya. 2011; 5(39):61-64.
Levchenko IL. Gender peculiarities of suprasegmental autonomic regulation in patients suffering from relapsing course of multiple sclerosis. Medytsyna siohodni i zavtra. 2011; 3(52):107-112.
Maltsev DV. Multiple sclerosis: the unresolved issues and prospects of research. Ukrainskyi nevrolohichnyi zhurnal. 2-13; 2(23):8-15.
Povorozniuk VV, Yefrimov AS, Mykhalchuk LM. Studying the vitamin D levels in patients with type II diabetes mellitus with obesity. Problemy endokrynnoi patolohii. 2013; 1:50-54.
Shmidt TE, Yakhno NN. Multiple sclerosis: a guide for physicians, 2nd edition. Moscow. MEDpress-inform. 2010; 20-21.
Verhel AO, Ovcharenko LS. Osteogenesis and immune processes in children. Zdorovie rebenka. 2009; 4(19):10-15.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.